Diagnostics
M&A led growth strategy to build a differentiated, full-spectrum IVD business
Avacta’s Diagnostics division is actively pursuing an M&A led growth strategy with a vision to build a full spectrum IVD business supporting healthcare professionals to diagnose disease and broadening access to diagnostics to enhance health, fitness and well-being.
Our M&A strategy is focused on the highest value parts of the diagnostics sector – innovative product development and the commercial routes to market in both the centralised hospital laboratory and decentralised healthcare markets.
In the highly competitive diagnostics market, Avacta’s proprietary Affimer® platform provides a powerful tool to differentiate our immunodiagnostic products to gain competitive advantage and grow the market share of acquired businesses.
